Physician profile
Robert S Tomchik
NPI 1376525121
$3,394.04
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $417 · 2021: $45.99 · 2022: $840 · 2023: $713 · 2024: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,248.25 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $327.22 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $249.31 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.31 | 2019-2024 | Jardiance |
| Allergan, INC. | $176.91 | 2019-2020 | |
| Pfizer INC. | $162.79 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $150.19 | 2019-2020 | |
| Abbott Laboratories | $144.48 | 2019-2024 | Freestyle Libre |
| Exact Sciences Corporation | $117.75 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $79.74 | 2019-2022 | |
| Glaxosmithkline, LLC. | $72.82 | 2022-2023 | Trelegy Ellipta |
| Amgen INC. | $71.65 | 2020-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $69.46 | 2023 | |
| Merck Sharp & Dohme LLC | $66.20 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $41.65 | 2023 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.02 | 2024 | Xifaxan |
| Astellas Pharma US INC | $36.30 | 2019-2024 | Veozah |
| Dexcom, INC. | $33.77 | 2023-2024 | Dexcom G6 Transmitter |
| Eisai INC. | $25.00 | 2024 | |
| Genentech USA, INC. | $21.52 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.44 | 2019 | |
| Sanofi Pasteur INC. | $15.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tomchik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.